NASDAQ$NEO
NeoGenomics Inc. · Q1 2020 earnings
Q1 2020 earnings · · Investor relations
Briefing
NeoGenomics reported an 11% increase in revenue, reaching $106 million.
NeoGenomics, Inc. reported an 11% increase in consolidated revenue to $106.0 million for the first quarter of 2020. Clinical Services revenue increased by 7.9% to $93.0 million, while Pharma Services revenue grew by 39.3% to $13.0 million. The company experienced a net loss of $7.0 million, compared to a net loss of $2.4 million in the first quarter of 2019.
- Consolidated revenue increased 10.9% to $106.0 million.
- Clinical Services revenue increased 7.9% to $93.0 million.
- Pharma Services revenue increased 39.3% to $13.0 million.
- Pharma Services backlog increased 46.5% to $147.7 million.
Headline financials
Revenue & EPS history
NeoGenomics · Revenue · Quarterly
$106M
Forward guidance
The long-term growth outlook remains compelling and the company expects to emerge from this situation stronger than ever.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2020
+2.1%
Avg return
Earnings day
+3.4%
Avg return
5 days after
+2.7%
Avg return
30 days after
53%
34 / 64 earnings
Positive
+28.1%
Q3 2013
Best reaction
-34.0%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.8% | +9.6% | +18.4% | |
| Q4 2025 | +0.5% | -13.1% | -28.1% | |
| Q3 2025 | -2.5% | -3.8% | +19.4% | |
| Q1 2025 | -34.0% | -22.8% | -26.1% | |
| Q4 2024 | -13.9% | -23.0% | -31.1% | |
| Q3 2024 | +9.3% | +11.5% | +21.6% | |
| Q2 2024 | +16.1% | +15.4% | +9.7% | |
| Q1 2024 | -8.3% | +0.5% | -8.0% | |
| Q4 2023 | +14.8% | +16.9% | +7.5% | |
| Q3 2023 | +9.6% | +3.2% | +19.1% | |
| Q2 2023 | -6.2% | -11.0% | -11.3% | |
| Q1 2023 | +19.2% | +26.4% | +13.9% | |
| Q4 2022 | +18.2% | +26.2% | +26.4% | |
| Q3 2022 | +23.1% | +58.5% | +70.0% | |
| Q2 2022 | +16.1% | +23.4% | +3.6% | |
| Q1 2022 | -10.1% | -10.1% | -18.1% | |
| Q4 2021 | +11.2% | +14.4% | -6.0% | |
| Q3 2021 | -11.1% | -6.7% | -34.5% | |
| Q2 2021 | -4.6% | -12.7% | +7.7% | |
| Q1 2021 | -11.6% | -19.5% | -14.0% | |
| Q4 2020 | -4.0% | +0.3% | -12.5% | |
| Q3 2020 | -5.0% | -6.5% | +9.0% | |
| Q2 2020 | +1.9% | +3.8% | +2.4% | |
| Q1 2020 | +2.4% | -14.1% | -8.7% | |
| Q4 2019 | -5.5% | -0.2% | -14.3% | |
| Q3 2019 | +11.3% | +8.7% | +23.7% | |
| Q2 2019 | +0.3% | +4.6% | +2.0% | |
| Q1 2019 | +2.9% | +11.3% | +2.4% | |
| Q4 2018 | +4.6% | +7.6% | +12.5% | |
| Q3 2018 | +15.0% | +12.1% | +3.7% | |
| Q2 2018 | -1.6% | -1.5% | -1.9% | |
| Q1 2018 | +5.2% | +7.0% | +21.1% | |
| Q4 2017 | +12.1% | +15.8% | +9.9% | |
| Q3 2017 | +4.2% | +3.2% | +12.2% | |
| Q2 2017 | +2.5% | +2.5% | +3.5% | |
| Q1 2017 | -11.6% | -12.2% | -13.3% | |
| Q4 2016 | +1.6% | +3.4% | -3.2% | |
| Q3 2016 | +11.6% | +10.1% | +29.4% | |
| Q2 2016 | -1.5% | -5.7% | -14.4% | |
| Q1 2016 | +5.8% | — | — | |
| Q4 2015 | +7.7% | — | — | |
| Q3 2015 | +0.7% | — | — | |
| Q2 2015 | -4.6% | — | — | |
| Q1 2015 | +0.0% | — | — | |
| Q4 2014 | +0.5% | — | — | |
| Q3 2014 | +6.0% | — | — | |
| Q2 2014 | +24.2% | — | — | |
| Q1 2014 | +8.9% | — | — | |
| Q4 2013 | -10.6% | — | — | |
| Q3 2013 | +28.1% | — | — | |
| Q2 2013 | -3.5% | — | — | |
| Q1 2013 | -1.1% | — | — | |
| Q4 2012 | -10.9% | — | — | |
| Q3 2012 | +0.0% | — | — | |
| Q2 2012 | -3.5% | — | — | |
| Q1 2011 | -0.6% | — | — | |
| Q1 2012 | +0.0% | — | — | |
| Q4 2011 | +0.6% | — | — | |
| Q3 2011 | +0.0% | — | — | |
| Q2 2011 | -3.4% | — | — | |
| Q4 2010 | -3.7% | — | — | |
| Q3 2010 | +9.1% | — | — | |
| Q2 2010 | +0.0% | — | — | |
| Q1 2010 | -1.4% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro